Autolus Therapeutics plc
AUTL
Cena:
$ 1.70
+0.05 (3.03%)
Valuace
100
Růst
60
Zdraví
100
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
AUTOLUS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
04-02-2026
LONDON AND GAITHERSBURG, MD., FEB. 04, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AU...
Více zde
AUTOLUS THERAPEUTICS ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE, PIPELINE ADVANCEMENTS AND OUTLOOK FOR 2026
12-01-2026
COMPANY EXPECTS PRELIMINARY UNAUDITED AUCATZYL® NET PRODUCT REVENUE OF APPROXIMATELY $24 MILLION FO...
Více zde
AUTOLUS THERAPEUTICS TO EVALUATE AUTOMATED MANUFACTURING OF AUCATZYL® (OBE-CEL) ON THE CELLARES CELL SHUTTLETM PLATFORM
06-01-2026
SOUTH SAN FRANCISCO, CALIF. & LONDON--(BUSINESS WIRE)--AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A CO...
Více zde
AUTOLUS THERAPEUTICS PRESENTS UPDATED CLINICAL DATA FROM THE CARLYSLE TRIAL IN PATIENTS WITH SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025
08-12-2025
AUTOLUS PRESENTED PRELIMINARY DATA FROM THE PHASE 1 CARLYSLE TRIAL IN PATIENTS WITH SEVERE REFRACTOR...
Více zde
AUTOLUS THERAPEUTICS PRESENTS INITIAL CLINICAL DATA IN PEDIATRIC R/R B-ALL PATIENTS AND OTHER ONCOLOGY DATA AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025
08-12-2025
OBE-CEL DEMONSTRATES HIGH REMISSION RATES IN PEDIATRIC PATIENTS WITH HIGH-RISK R/R B-ALL WITH OVERAL...
Více zde
AUTOLUS THERAPEUTICS APPOINTS RYAN RICHARDSON TO BOARD OF DIRECTORS
01-12-2025
LONDON AND GAITHERSBURG, MD., DEC. 01, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AU...
Více zde
NICE RECOMMENDS AUCATZYL® (OBECABTAGENE AUTOLEUCEL) AS A TREATMENT OPTION FOR ADULT PATIENTS (≥26 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)¹
25-11-2025
LONDON, NOV. 25, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCI...
Více zde
AUTOLUS THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON
13-11-2025
LONDON AND GAITHERSBURG, MD., NOV. 13, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AU...
Více zde
AUTOLUS THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES
12-11-2025
COMPANY REPORTS Q3 2025 AUCATZYL® NET PRODUCT REVENUE OF $21.1 MILLION AND DEFERRED REVENUE OF $7.6...
Více zde
AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATES AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025
03-11-2025
LONDON AND GAITHERSBURG, MD., NOV. 03, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AU...
Více zde
AUTOLUS THERAPEUTICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 12, 2025
30-10-2025
LONDON & GAITHERSBURG, MD., OCT. 30, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUT...
Více zde
AUTOLUS THERAPEUTICS PRESENTS CLINICAL DATA UPDATES AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025
27-10-2025
DATA FROM THE PHASE 1 CARLYSLE STUDY IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE) SUGGE...
Více zde
AUTOLUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
20-10-2025
LONDON AND GAITHERSBURG, MD., OCT. 20, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AU...
Více zde
AUTOLUS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
15-10-2025
LONDON AND GAITHERSBURG, MD., OCT. 15, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AU...
Více zde
AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATE AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025
16-09-2025
AUTOLUS ANNOUNCES THE PUBLICATION OF AN ABSTRACT SUBMITTED TO THE AMERICAN COLLEGE OF RHEUMATOLOGY (...
Více zde
AUTOLUS THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES
12-08-2025
COMPANY REPORTS Q2 2025 AUCATZYL® NET PRODUCT REVENUE OF $20.9 MILLION AND $29.9 FOR THE FIRST SIX ...
Více zde
AUTOLUS THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 12, 2025
24-07-2025
LONDON AND GAITHERSBURG, MD., JULY 24, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: A...
Více zde
AUTOLUS THERAPEUTICS' CAR T THERAPY AUCATZYL® (OBECABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)
21-07-2025
APPROVAL IS BASED ON FELIX CLINICAL TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN ADULT PATIENTS WIT...
Více zde
AUTOLUS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
15-07-2025
LONDON & GAITHERSBURG, MD., JULY 15, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUT...
Více zde
AUTOLUS THERAPEUTICS PRESENTS LONG-TERM FOLLOW UP FROM THE FELIX STUDY DEMONSTRATING OBE-CEL'S POTENTIAL FOR LONG-TERM REMISSION IN R/R B-ALL AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS
12-06-2025
MEDIAN DURATION OF RESPONSE IN FELIX STUDY NOW 42.6 MONTHS AFTER AN ADDITIONAL 11 MONTHS OF FOLLOW U...
Více zde
AUTOLUS THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
29-05-2025
LONDON, MAY 29, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCI...
Více zde
AUTOLUS THERAPEUTICS ANNOUNCES POSITIVE CHMP OPINION FOR OBECABTAGENE AUTOLEUCEL FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)
23-05-2025
AUTOLUS THERAPEUTICS ANNOUNCES POSITIVE CHMP OPINION FOR OBECABTAGENE AUTOLEUCEL FOR ADULT PATIENTS ...
Více zde
AUTOLUS THERAPEUTICS PRESENTS CLINICAL DATA UPDATES AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS
14-05-2025
LONDON, MAY 14, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCI...
Více zde
AUTOLUS THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES
08-05-2025
COMPANY REPORTS Q1 2025 AUCATZYL® NET PRODUCT REVENUE OF $9.0 MILLION U.K. MEDICINES AND HEALTHCARE...
Více zde
AUTOLUS THERAPEUTICS ANNOUNCES LICENSE OF AUCATZYL® (OBECABTAGENE AUTOLEUCEL) ISSUED BY UK MHRA FOR ADULT PATIENTS (≥ 18 YEARS) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)(1)
25-04-2025
AUTOLUS THERAPEUTICS ANNOUNCES LICENSE OF AUCATZYL® (OBECABTAGENE AUTOLEUCEL) ISSUED BY UK MHRA FOR...
Více zde
AUTOLUS THERAPEUTICS HIGHLIGHTS ADVANCING AUTOIMMUNE PIPELINE AT R&D INVESTOR EVENT
23-04-2025
COMPANY OUTLINED POTENTIAL FOR VALUE CREATION DRIVEN BY OBE-CEL ACROSS MULTIPLE B CELL DRIVEN MALIGN...
Více zde
AUTOLUS THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MAY 8, 2025
22-04-2025
LONDON, APRIL 22, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMER...
Více zde
AUTOLUS THERAPEUTICS TO PARTICIPATE IN THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
02-04-2025
LONDON, APRIL 02, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMER...
Více zde
AUTOLUS THERAPEUTICS TO HOST R&D INVESTOR EVENT ON WEDNESDAY, APRIL 23, 2025
01-04-2025
LONDON, APRIL 01, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMER...
Více zde
AUTOLUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATES
20-03-2025
AUCATZYL® (OBECABTAGENE AUTOLEUCEL) U.S. COMMERCIAL LAUNCH PROGRESSING ON TRACK WITH 33 AUTHORIZED ...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2026-01-26 00:00:00 | 8-K |  | Stáhnout |
| 2026-01-12 00:00:00 | 8-K | | Stáhnout |
| 2025-12-02 00:00:00 | 8-K | | Stáhnout |
| 2025-11-12 00:00:00 | 8-K | | Stáhnout |
| 2025-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2025-08-12 01:00:00 | 8-K | | Stáhnout |
| 2025-08-12 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-12 00:00:00 | 8-K | | Stáhnout |
| 2025-08-12 00:00:00 | 10-Q | | Stáhnout |
| 2025-06-27 01:00:00 | 8-K | | Stáhnout |
| 2025-06-27 00:00:00 | 8-K | | Stáhnout |
| 2025-06-02 01:00:00 | 8-K | | Stáhnout |
| 2025-06-02 00:00:00 | 8-K | | Stáhnout |
| 2025-05-30 01:00:00 | 8-K | | Stáhnout |
| 2025-05-30 00:00:00 | 8-K | | Stáhnout |
| 2025-05-08 01:00:00 | 8-K | | Stáhnout |
| 2025-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-08 00:00:00 | 8-K | | Stáhnout |
| 2025-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2025-04-23 01:00:00 | 8-K | | Stáhnout |
| 2025-04-23 00:00:00 | 8-K | | Stáhnout |
| 2025-04-03 01:00:00 | 8-K | | Stáhnout |
| 2025-04-03 00:00:00 | 8-K | | Stáhnout |
| 2025-03-20 00:00:00 | 8-K | | Stáhnout |
| 2025-03-20 00:00:00 | 10-K | | Stáhnout |
| 2025-03-19 23:00:00 | 8-K | | Stáhnout |
| 2025-03-19 23:00:00 | 10-K | | Stáhnout |
| 2025-01-13 00:00:00 | 8-K | | Stáhnout |
| 2025-01-12 23:00:00 | 8-K | | Stáhnout |
| 2024-11-12 00:00:00 | 8-K | | Stáhnout |
| 2024-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-11 23:00:00 | 8-K | | Stáhnout |
| 2024-11-11 23:00:00 | 10-Q | | Stáhnout |
| 2024-09-26 01:00:00 | 8-K | | Stáhnout |
| 2024-09-26 00:00:00 | 8-K | | Stáhnout |
| 2024-09-19 01:00:00 | 8-K | | Stáhnout |
| 2024-09-19 00:00:00 | 8-K | | Stáhnout |
| 2024-09-13 01:00:00 | 8-K | | Stáhnout |
| 2024-09-13 00:00:00 | 8-K | | Stáhnout |
| 2024-08-08 01:00:00 | 8-K | | Stáhnout |
| 2024-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 00:00:00 | 8-K | | Stáhnout |
| 2024-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-06-28 01:00:00 | 8-K | | Stáhnout |
| 2024-06-28 00:00:00 | 8-K | | Stáhnout |
| 2024-06-05 01:00:00 | 8-K | | Stáhnout |
| 2024-06-05 00:00:00 | 8-K | | Stáhnout |
| 2024-06-03 01:00:00 | 8-K | | Stáhnout |
| 2024-06-03 00:00:00 | 8-K | | Stáhnout |
| 2024-05-17 01:00:00 | 8-K | | Stáhnout |
| 2024-05-17 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-17 00:00:00 | 8-K | | Stáhnout |
| 2024-05-17 00:00:00 | 10-Q | | Stáhnout |
| 2024-05-13 01:00:00 | 8-K | | Stáhnout |
| 2024-05-13 00:00:00 | 8-K | | Stáhnout |
| 2024-04-01 01:00:00 | 8-K | | Stáhnout |
| 2024-04-01 00:00:00 | 8-K | | Stáhnout |
| 2024-03-21 00:00:00 | 8-K | | Stáhnout |
| 2024-03-21 00:00:00 | 10-K | | Stáhnout |
| 2024-03-20 23:00:00 | 8-K | | Stáhnout |
| 2024-03-20 23:00:00 | 10-K | | Stáhnout |
| 2024-03-14 00:00:00 | 8-K | | Stáhnout |
| 2024-03-13 23:00:00 | 8-K | | Stáhnout |
| 2024-02-13 00:00:00 | 8-K | | Stáhnout |
| 2024-02-12 23:00:00 | 8-K | | Stáhnout |
| 2024-02-08 00:00:00 | 8-K | | Stáhnout |
| 2024-02-07 23:00:00 | 8-K | | Stáhnout |
| 2024-01-26 00:00:00 | 8-K | | Stáhnout |
| 2024-01-25 23:00:00 | 8-K | | Stáhnout |
| 2024-01-10 00:00:00 | 8-K | | Stáhnout |
| 2024-01-09 23:00:00 | 8-K | | Stáhnout |
| 2023-12-22 00:00:00 | 8-K | | Stáhnout |
| 2023-12-21 23:00:00 | 8-K | | Stáhnout |
| 2023-12-11 00:00:00 | 8-K | | Stáhnout |
| 2023-12-10 23:00:00 | 8-K | | Stáhnout |
| 2023-11-27 00:00:00 | 8-K | | Stáhnout |
| 2023-11-26 23:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-08 23:00:00 | 8-K | | Stáhnout |
| 2023-11-08 23:00:00 | 10-Q | | Stáhnout |
